ACME Resources Corp. has filed a non-offering preliminary prospectus for the purpose of qualifying Acme Resources for listing on the Canadian Securities Exchange (CSE).
ACME Resources intends to apply for a listing of its common shares on the CSE.
ACME Resources was originally listed as a capital pool company and most recently traded on the NEX Tier of the TSX Venture Exchange under the symbol ACY.H. Its shares were delisted from NEX on March 28, 2018.
On April 9, 2018, ACME Resources signed the definitive agreement with Rapid Dose Therapeutics Inc. (RDT) for or a three-cornered amalgamation transaction which would constitute a proposed reverse take-over of ACME by RDT.
Vancouver based Rapid Dose Therapeutics is a Canadian pharma-technology company that provides proprietary oral and non-invasive drug delivery technologies designed for applications of nutraceuticals, active pharmaceutical ingredients, and other healthcare products. RDT provides product innovation, production, and consultation to the pharmaceutical and healthcare manufacturing industry.
Rapid Dose Therapeutics is led by CEO & Director Mark Upsdell, and SVP & Director, Jason Lewis, who are the two largest shareholders.
photo credit: RDT
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- Bridgit discloses BDC Capital led $6.24M Series A - March 18, 2019
- AEPONYX secures $7.9M Series A led by Pangaea Ventures - March 14, 2019
- BrandProject to raise second fund - March 14, 2019